Abstract
This paper examines the opportunities and challenges pharmaceutical companies encounter when considering entry into the niche US veterinary generics market. The key points compare the growth of the companion animal market as an attractive lure for potential entrants, to the regulatory hurdles of drug approval, drug distribution and veterinarian relationships and education that could dissuade companies from testing the waters of veterinary generics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
